Research
And Grants
Note: When clicking the "Submit Grant Application" button below you will be redirected to SnapGrant.com to complete the application process.
Submit Grant ApplicationThe Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.
The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.
Funding of PBTCF 2020: PBTC-058 - $25,000
$25,000.00
January 2020
PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Sydney Children's Hospital - $151,468
$151,468.00
December 2019
Developing New Epigenetic Combination Treatments Against DIPG.
Oncoceutics ONC201 - $100,000
$100,000.00
December 2019
Expansion of the ONC201 Compassionate Use.
University of Sydney - $100,000
$100,000.00
November 2019
Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an approach of radiosensitization for diffuse intrinsic pontine gliomas.
University of Michigan Hospitals - $157,856
$157,856.00
November 2019
Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG
Dayton Children's Hospital - $69,600
$69,600.00
November 2019
Responses of distinct cell populations to PDGFRA inhibitors in diffuse intrinsic pontine glioma.
Institute of Cancer Research - $121,863
$121,863.00
November 2019
Targeting Top3A-Amplified DIPG cells by Sirtuin inhibition.
Bambino Gesu Children's Hospital - $49,803
$49,803.00
August 2019
Using imaging mass cytometry to identify next generation imaging biomarkers in PHGG and DIPG.
Telethon Kids Institute - $49,512
$49,512.00
August 2019
Development of a new and effective therapy against Diffuse Intrinsic Pontine Glioma.
Oncoceutics ONC201 - Phase II - $83,333
$83,333.00
May 2019
Expansion of the ONC201 Compassionate Use.
Funding of PBTCF 2019: PBTC-058 - $25,000
$25,000.00
January 2019
PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Sydney Children’s Hospital - $175,089
$175,089.00
November 2018
Polyamine Pathway Metabolism as a Novel Therapeutic Option for Diffuse Intrinsic Pontine Glioma
Cincinnati Children's Hospital - $540,742
$540,742.00
November 2018
Expansion of the International DIPG Registry.
Bambino Gesú Children's Hospital - $99,382
$99,382.00
November 2018
Investigating the Role of DIPG-Derived Exosomes in Tumor Growth and Invasion.
Ann and Robert H. Lurie Children's Hospital of Chicago - $35,000
$35,000.00
November 2018
Credentialing an Improved DIPG Mouse Model.